CD8A and neoplasm: These and similar observations(39) confirmed that the binding of CD94/NKG2A with HLA class-I on tumor cells protected them from cytotoxic killing by both NK cells and a subset of CD8+ T cells, although the precise mechanism remained to be clarified.